%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2020-04-13T12:33:03-04:00
2020-04-13T12:33:06-04:00
2020-04-13T12:33:06-04:00
Adobe InDesign CC 13.1 (Windows)
uuid:818f6afa-4ce9-487e-b86b-e6c006b31e88
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:a96c5920-218b-6b4f-b703-e47352a069e6
proof:pdf
xmp.iid:64408ed9-1e45-c544-9938-9c57d6b96f58
xmp.did:54737477-a834-2449-95e8-c3d663b4bee9
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 13.1 (Windows)
/
2020-04-13T12:33:03-04:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
12 0 obj
<>
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
14 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
40 0 obj
<>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.01 Tc 8.5 0 0 8.5 171 283.838 Tm
(1.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(In the Cuttler et al study)92 (, medicinal cannabis)-9.9 ( )]TJ
0 -1.2 Td
[(use is associated with reduction of headache)-9.9 ( )]TJ
0 -1.2 Td
(and migraine relief:)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 -1.2 Td
[(a. in more than 80% of respondents in this)-10 ( )]TJ
0 -1.2 Td
[(double-blind, placebo-controlled study with)-10 ( )]TJ
0 -1.2 Td
(volunteers from numerous headache clinics.)Tj
0 -1.2 Td
[(b. in more than 80% of respondents in this)-10 ( )]TJ
0 -1.2 Td
[(observational study with volunteers using an)-10 ( )]TJ
0 -1.2 Td
(anonymous app to record responses.)Tj
0 -1.2 Td
[(c. in fewer than half of migraine respondents)-10 ( )]TJ
0 -1.2 Td
[(and close to 80% of those with headache in)-10 ( )]TJ
0 -1.2 Td
[(this double-blind, placebo-controlled study)-10 ( )]TJ
0 -1.2 Td
[(with volunteers from numerous headache)-10 ( )]TJ
0.01 Tw 0 -1.2 Td
(clinics.)Tj
0 Tw 0 -1.2 Td
[(d. in fewer than half of headache respondents)-9.9 ( )]TJ
0 -1.2 Td
[(and close to 80% of those with migraine in)-10 ( )]TJ
0 -1.2 Td
[(this observational study with volunteers using)-10 ( )]TJ
0 -1.2 Td
(an anonymous app to record responses.)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.005 Tw 21.308 20.4 Td
(2.)Tj
/Span<>> BDC
[( )-99.5 ( )]TJ
EMC
1.588 0 Td
[(In patients with atrial \037brillation and advanced)-10 ( )]TJ
0 Tw 0 -1.2 Td
[(kidney disease \(glomerular \037ltration rate lower)-10 ( )]TJ
0 -1.2 Td
(than 30 mL/min\), the best treatment is:)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 -1.2 Td
(a. no anticoagulation.)Tj
0 -1.2 Td
(b. aspirin.)Tj
0 -1.2 Td
(c. a direct oral anticoagulant.)Tj
0 -1.2 Td
(d. a vitamin K antagonist.)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-1.588 -2.4 Td
(3.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(In patients who are > age 75 years and who)-10 ( )]TJ
0 -1.2 Td
[(have possible angina pectoris, the best initial)-9.9 ( )]TJ
0 -1.2 Td
(test is:)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 -1.2 Td
[(a. invasive coronary angiography)92.1 (.)]TJ
0 -1.2 Td
[(b. CT angiography)92 (.)]TJ
0 -1.2 Td
(c. CT coronary calcium score.)Tj
0 -1.2 Td
(d. stress testing.)Tj
ET
0 0 0 0.2 K
13 w
/GS0 gs
q 1 0 0 1 263.8253 555.6873 cm
0 0 m
77.329 0 l
S
Q
q 1 0 0 1 163.2662 543.6157 cm
0 0 m
189.363 0 l
S
Q
q 1 0 0 1 163.2662 531.5442 cm
0 0 m
70.78 0 l
S
Q
BT
/GS1 gs
-0.03 Tc 10 0 0 10 163.2662 733.7599 Tm
(24-week open label treatment period.)Tj
0 Tc 5.83 0 0 5.83 314.1445 737.09 Tm
(1)Tj
-0.03 Tc 10 0 0 10 317.2111 733.7599 Tm
[( The)-30 ( )]TJ
-15.394 -1.207 Td
[(primary ef\037cacy endpoint was based on the)-30 ( )]TJ
0 -1.207 Td
[(randomized withdrawal phase. Most CD)-30 ( )]TJ
0 -1.207 Td
[(subjects had undergone surgery and had)-30 ( )]TJ
0 -1.207 Td
[(persistence or recurrence of disease \(mean)-30 ( )]TJ
0 -1.207 Td
[(of three 24-hour urine-free cortisol [mUFC])-30 ( )]TJ
0 -1.207 Td
[(> 1.5 time upper limit of normal [ULN]\).)-30 ( )]TJ
0 -1.207 Td
[(The median mUFC was 476 nmole/24 hr)111 (,)-30 ( )]TJ
0 -1.207 Td
[(or approximately 3.5 \327 ULN. The primary)-30 ( )]TJ
0 -1.207 Td
[(endpoint was the percentage of complete)-29.9 ( )]TJ
0 -1.207 Td
[(responders at the end of the randomized)-30 ( )]TJ
0 -1.207 Td
[(withdrawal phase. Response was mUFC)-30 ( )]TJ
0 -1.207 Td
[(< ULN at the end of the maintenance)-30 ( )]TJ
0 -1.207 Td
[(period. After 24 weeks, 71 responders were)-29.9 ( )]TJ
0 -1.207 Td
[(randomized to osilodrostat \(n = 36\) or placebo)-30 ( )]TJ
0 -1.207 Td
(\(n = 35\) for eight weeks. )Tj
[(At the end of eight)-30 ( )]TJ
0 -1.207 Td
[(weeks, response was 86% for osilodrostat and)-30 ( )]TJ
0 -1.207 Td
(29% for placebo.)Tj
[( It is unclear if osilodrostat)-30 ( )]TJ
0 -1.207 Td
[(improved cardiovascular and metabolic)-30 ( )]TJ
0 -1.207 Td
[(parameters \(e.g., blood pressure, body weight,)-30 ( )]TJ
0 -1.207 Td
[(waist circumference, HbA1c\). Currently)92 (, there)-30 ( )]TJ
0 -1.207 Td
[(are no direct comparisons to pasireotide.)-30 ( )]TJ
0 -1.207 Td
[(However)111 (, in a Phase III study of pasireotide,)-30 ( )]TJ
0 -1.207 Td
[(subjects received two doses \(0.6 mg twice daily)-30 ( )]TJ
0 -1.207 Td
[(or 0.9 mg twice daily\), with response rates of)-30 ( )]TJ
0 -1.207 Td
[(15% and 26% at six months, respectively)92 (.)]TJ
0.03 Tw 5.83 0 0 5.83 333.7149 435.3021 Tm
(4,5)Tj
0 Tc 0 Tw 10 0 0 10 341.4688 431.9721 Tm
( )Tj
-0.03 Tc -17.82 -1.207 Td
[(There was a high frequency of hyperglycemia)-30 ( )]TJ
0 -1.207 Td
[(in pasireotide-treated subjects \(40%\), with)-30 ( )]TJ
0 -1.207 Td
(46% requiring glucose-lowering medications.)Tj
/TT0 1 Tf
0.025 Tc 0 -2.414 Td
[(CLINICAL IMPLICA)72.7 (TIONS)]TJ
/T1_1 1 Tf
-0.03 Tc 0 -1.207 Td
[(CD is caused by a pituitary tumor)110.9 (, resulting)-30 ( )]TJ
0 -1.207 Td
[(in excess secretion of adrenocorticotropin)-30 ( )]TJ
0 -1.207 Td
[(and subsequent excess production of cortisol)-30 ( )]TJ
ET
/GS0 gs
q 1 0 0 1 507.2272 700.3223 cm
0 0 m
44.079 0 l
S
Q
q 1 0 0 1 366.1287 688.1764 cm
0 0 m
177.518 0 l
S
Q
q 1 0 0 1 366.1287 676.0305 cm
0 0 m
105.849 0 l
S
Q
q 1 0 0 1 471.9777 676.6105 cm
0 0 m
8.104 0 l
S
Q
q 1 0 0 1 480.0814 676.0305 cm
0 0 m
67.689 0 l
S
Q
q 1 0 0 1 366.1287 663.8846 cm
0 0 m
189.363 0 l
S
Q
q 1 0 0 1 366.1287 651.7388 cm
0 0 m
181.528 0 l
S
Q
q 1 0 0 1 366.1287 639.5929 cm
0 0 m
189.008 0 l
S
Q
q 1 0 0 1 366.1287 627.447 cm
0 0 m
30.98 0 l
S
Q
q 1 0 0 1 397.1084 628.027 cm
0 0 m
3.241 0 l
S
Q
q 1 0 0 1 400.3499 627.447 cm
0 0 m
151.148 0 l
S
Q
q 1 0 0 1 366.1287 615.3011 cm
0 0 m
184.348 0 l
S
Q
q 1 0 0 1 366.1287 603.1553 cm
0 0 m
170.878 0 l
S
Q
q 1 0 0 1 537.0065 603.7353 cm
0 0 m
3.241 0 l
S
Q
q 1 0 0 1 540.2479 603.1553 cm
0 0 m
2.48 0 l
S
Q
q 1 0 0 1 366.1287 591.0094 cm
0 0 m
169.119 0 l
S
Q
q 1 0 0 1 366.1287 578.8635 cm
0 0 m
189.363 0 l
S
Q
q 1 0 0 1 366.1287 566.7176 cm
0 0 m
187.308 0 l
S
Q
q 1 0 0 1 366.1287 554.5717 cm
0 0 m
182.659 0 l
S
Q
q 1 0 0 1 366.1287 542.4258 cm
0 0 m
90.759 0 l
S
Q
BT
/GS1 gs
10 0 0 10 366.1287 733.7599 Tm
(by the adrenal cortex.)Tj
0.03 Tw 5.83 0 0 5.83 453.9878 737.09 Tm
(6-8)Tj
0 Tw 10 0 0 10 461.8874 733.7599 Tm
[( It is a rare disease)-30 ( )]TJ
-9.576 -1.215 Td
[(that is more common in women and leads)-30 ( )]TJ
0 -1.215 Td
[(to signi\037cant morbidities, mortality)92 (, and)-30 ( )]TJ
0 -1.215 Td
(health-related quality of life issues. )Tj
0.03 Tw [(T)67 (reatment)-30 ( )]TJ
0 Tw 0 -1.215 Td
[(of choice is pituitary surgery)92 (, with complete)-29.9 ( )]TJ
0 -1.215 Td
(remission rate of 60-90%.)Tj
0 Tc 5.83 0 0 5.83 471.9777 676.3605 Tm
(7,9)Tj
-0.03 Tc 10 0 0 10 480.0814 673.0305 Tm
[( In patients who)-30 ( )]TJ
-11.395 -1.215 Td
[(are not cured or are not candidates for surgery)92 (,)-30 ( )]TJ
0 -1.215 Td
[(treatment options include pasireotide, which)-30 ( )]TJ
0 -1.215 Td
[(may be useful for milder disease with UFC < 2)-30 ( )]TJ
0 -1.215 Td
(\327 ULN.)Tj
0 Tc 5.83 0 0 5.83 397.1084 627.777 Tm
(9)Tj
-0.03 Tc 10 0 0 10 400.3499 624.447 Tm
[( However)111 (, the drug frequently causes)-30 ( )]TJ
-3.422 -1.215 Td
[(hyperglycemia. Ketoconazole also has shown)-30 ( )]TJ
0 -1.215 Td
[(effectiveness, but can cause hepatotoxicity)92 (.)]TJ
0 Tc 5.83 0 0 5.83 537.0065 603.4853 Tm
(9)Tj
10 0 0 10 540.2479 600.1553 Tm
( )Tj
-0.03 Tc -17.412 -1.215 Td
[(Osilodrostat offers a new option, with an)-30 ( )]TJ
0 -1.215 Td
[(estimated response rate slightly over 50%. It is)-30 ( )]TJ
0 -1.215 Td
[(expected to be available in the second or third)-30 ( )]TJ
0 -1.215 Td
[(quarter of 2020. The cost was unavailable at)-30 ( )]TJ
0 -1.215 Td
[(the time of this review)91.9 (.)]TJ
0 Tc ( )Tj
/C2_0 1 Tf
/Span<>> BDC
<0084>Tj
EMC
/TT0 1 Tf
0.01 Tc -0.01 Tw 9.25 0 0 9.25 366.1287 513.7341 Tm
(REFERENCES)Tj
/TT1 1 Tf
-0.025 Tc 0 Tw 0 -1.205 Td
(1.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(R)17.5 (ecordati R)-36.7 (are Diseases, Inc. Isturisa P)35.7 (rescribing)-24.9 ( )]TJ
0 -1.205 Td
(Information, March 2020.)Tj
-1.946 -1.205 Td
(2.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
(Duggan S. )Tj
/TT2 1 Tf
0.025 Tw (Drugs)Tj
/TT1 1 Tf
0 Tw ( 2020;80:495-500.)Tj
-1.946 -1.205 Td
(3.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
(Creemers SG, et al. )Tj
/TT2 1 Tf
(J Clin Endocrinol Metab)Tj
/TT1 1 Tf
0 Tc 15.492 0 Td
( )Tj
-0.025 Tc 0.025 Tw -15.492 -1.205 Td
(2019;104:3437-3449.)Tj
0 Tw -1.946 -1.205 Td
(4.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
(Colao A, et al. )Tj
/TT2 1 Tf
(N Engl J Med)Tj
/TT1 1 Tf
( 2012;366:914-924.)Tj
-1.946 -1.205 Td
(5.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(Novartis. Signifor P)35.7 (rescribing Information,)-24.9 ( )]TJ
0 Tc 14.973 0 Td
( )Tj
-0.025 Tc -14.973 -1.205 Td
(January 2020.)Tj
-1.946 -1.205 Td
(6.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(F)35.9 (ood and Drug Administration. FD)17.6 (A approves new)-24.8 ( )]TJ
0 -1.205 Td
[(treatment for adults with Cushing\222s disease, March)-24.8 ( )]TJ
0 -1.205 Td
(6, 2020.)Tj
-1.946 -1.205 Td
(7.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(W)54.9 (en YH)17.5 (, et al. )]TJ
/TT2 1 Tf
(J Clin Med)Tj
/TT1 1 Tf
( 2019;8. doi: 10.3390/)Tj
0.025 Tw 0 -1.205 Td
(jcm8111961.)Tj
0 Tw -1.946 -1.205 Td
(8.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(L)17.5 (au D, et al. )]TJ
/TT2 1 Tf
[(Neurosurg F)35.5 (ocus)]TJ
/TT1 1 Tf
( 2015;38:E11.)Tj
-1.946 -1.205 Td
(9.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
(Nieman LK, et al. )Tj
/TT2 1 Tf
(J Clin Endocrinol Metab)Tj
/TT1 1 Tf
0 Tc 14.586 0 Td
( )Tj
-0.025 Tc 0.025 Tw -14.586 -1.205 Td
(2015;100:2807-2831.)Tj
ET
endstream
endobj
41 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
/CS0 cs 0.07 scn
/GS0 gs
18 102.17 120.33 653.83 re
f
18 36 539.325 53.473 re
f
BT
0 0 0 1 k
/GS1 gs
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 7 0 0 7 27.8983 78.3659 Tm
(Interested in reprints or posting an article to your )Tj
0 -1.143 Td
[(company)-55.8 (\222s site? There are numerous opportunities for )]TJ
0 -1.143 Td
(you to leverage editorial recognition for the benefit of )Tj
0 -1.143 Td
(your brand. Call us at \(800\) 688-2421 or email us at )Tj
0 -1.143 Td
(reprints@reliasmedia.com.)Tj
25.217 4.571 Td
(Discounts are available for group subscriptions, multiple )Tj
0 -1.143 Td
(copies, site licenses, or electronic distribution. For pricing )Tj
0 -1.143 Td
(information, please contact our Group Account Managers )Tj
0 -1.143 Td
(at groups@reliasmedia.com or \(866\) 213-0844.)Tj
19.248 0 Td
( )Tj
5.969 3.429 Td
[(T)175 (o reproduce any part of R)17.6 (elias Media newsletters for )]TJ
0 -1.143 Td
(educational purposes, please contact The Copyright )Tj
0 -1.143 Td
(Clearance Center for permission at info@copyright.com )Tj
0 -1.143 Td
(or \(978\) 750-8400.)Tj
ET
/CS0 CS 1 SCN
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 138.6633 754.5 cm
0 0 m
437.337 0 l
S
Q
/CS0 cs 1 scn
163.328 300.513 392.414 18.174 re
f
0.25 w
163.391 102.045 392.225 198.79 re
S
BT
0 scn
0.037 Tc -0.012 Tw 10 0 0 10 318.7734 306.7422 Tm
[(C)-3.7 (M)-3 (E)12 ( Q)1.9 (U)-3.3 (E)5.9 (S)4.8 (T)10.1 (ION)-11.3 (S)]TJ
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
0 Tc 0 Tw 6 0 0 6 25.2 744.168 Tm
(PHYSICIAN EDITOR)Tj
/TT0 1 Tf
0 -1.167 Td
(Stephen A. Brunton, MD)Tj
/TT1 1 Tf
-0.025 Tc 0 -1.167 Td
[(Adjunct P)35.6 (rofessor of Pharmacy P)35.7 (ractice)]TJ
0 -1.167 Td
(College of Pharmacy)Tj
0 Tc 7.469 0 Td
( )Tj
-0.025 Tc -7.469 -1.167 Td
[(R)17.5 (oseman University of Health Sciences)]TJ
0 Tc 13.998 0 Td
( )Tj
-0.025 Tc -13.998 -1.167 Td
[(Salt L)17.4 (ake City)]TJ
/T1_0 1 Tf
0 Tc 0 -2.667 Td
(PEER REVIEWER)Tj
/TT0 1 Tf
0 -1.167 Td
[(Gerald R)17.7 (oberts, MD)]TJ
/TT1 1 Tf
0 -1.167 Td
(Senior Attending Physician )Tj
( )Tj
0 -1.167 Td
[(L)17.4 (ong Island Jewish Medical Center)]TJ
13.107 0 Td
( )Tj
-13.107 -1.167 Td
(NS/LIJ Health Care System)Tj
10.378 0 Td
( )Tj
-10.378 -1.167 Td
[(New Hyde P)54.8 (ark, NY)]TJ
/T1_0 1 Tf
0 -2.333 Td
[(EDITORIAL ADVISOR)92.1 (Y BOARD)]TJ
/TT0 1 Tf
0 -1.167 Td
(James Chan, PharmD, PhD)Tj
/TT1 1 Tf
0 -1.167 Td
[(Associate Clinical P)34.4 (rofessor)]TJ
( )Tj
0 -1.167 Td
(School of Pharmacy)Tj
7.563 0 Td
( )Tj
-7.563 -1.167 Td
(University of California)Tj
8.642 0 Td
( )Tj
-8.642 -1.167 Td
[(San F)54.9 (rancisco)]TJ
/TT0 1 Tf
0 -1.917 Td
[(William T)156.1 (. Elliott, MD, F)36.2 (A)17.5 (CP)]TJ
/TT1 1 Tf
0 -1.167 Td
[(Assistant Clinical P)33.9 (rofessor of Medicine )]TJ
0 -1.167 Td
(University of California)Tj
8.642 0 Td
( )Tj
-8.642 -1.167 Td
[(San F)54.9 (rancisco)]TJ
/TT0 1 Tf
0 -1.917 Td
(David Fiore, MD)Tj
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor of F)35.9 (amily Medicine)]TJ
0 -1.167 Td
(University of Nevada)Tj
( )Tj
0 -1.167 Td
[(R)17.5 (eno)]TJ
/TT0 1 Tf
0 -1.917 Td
[(K)17.7 (en Grauer)100.9 (, MD)]TJ
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor Emeritus in F)35.1 (amily )]TJ
( )Tj
0 -1.167 Td
(Medicine, College of Medicine,)Tj
0 -1.167 Td
(University of Florida)Tj
0 -1.167 Td
(Gainesville)Tj
/TT0 1 Tf
0 -1.917 Td
(Seema Gupta, MD, MSPH)Tj
/TT1 1 Tf
0 -1.167 Td
[(Clinical Assistant P)33.9 (rofessor)]TJ
0 -1.167 Td
[(Department of F)35.5 (amily )]TJ
( )Tj
0 -1.167 Td
(and Community Health)Tj
( )Tj
0 -1.167 Td
(Joan C. Edwards School of Medicine)Tj
0 -1.167 Td
(Marshall University)Tj
0 -1.167 Td
(Huntington, WV)Tj
/TT0 1 Tf
0 -1.917 Td
[(Martin S. Lipsky)87.5 (, MD)]TJ
/TT1 1 Tf
-0.03 Tc 0.03 Tw 0 -1.167 Td
(Chancellor)Tj
0 Tc 0 Tw 3.889 0 Td
( )Tj
-0.03 Tc -3.889 -1.167 Td
(South Jordan Campus)Tj
0 Tc 7.847 0 Td
( )Tj
-0.03 Tc -7.847 -1.167 Td
[(R)17.5 (oseman University of Health Sciences)]TJ
0 Tc 13.818 0 Td
( )Tj
-0.03 Tc -13.818 -1.167 Td
(South Jordan, UT)Tj
/TT0 1 Tf
0 Tc 0 -1.917 Td
[(Joseph E. Scherger)101.6 (, MD, MPH)]TJ
/TT1 1 Tf
0 -1.167 Td
[(Core F)35.8 (aculty)]TJ
0 -1.167 Td
[(Eisenhower Health F)35.5 (amily Medicine )]TJ
13.922 0 Td
( )Tj
-13.922 -1.167 Td
[(R)17.5 (esidency P)35.5 (rogram)]TJ
0 -1.167 Td
[(Eisenhower Health Center)99.9 (, L)17.5 (a Quinta, CA)]TJ
0 -1.167 Td
[(Clinical P)34.8 (rofessor)]TJ
0 -1.167 Td
[(K)17.6 (eck School of Medicine)]TJ
0 -1.167 Td
(University of Southern California)Tj
12.409 0 Td
( )Tj
-12.409 -1.167 Td
[(L)17.4 (os Angeles)]TJ
/TT0 1 Tf
0 -1.917 Td
(Allan J. Wilke, MD, MA)Tj
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor and Chair)]TJ
7.542 0 Td
( )Tj
-7.542 -1.167 Td
[(Department of F)35.5 (amily Medicine)]TJ
12.045 0 Td
( )Tj
-12.045 -1.167 Td
[(W)54.9 (estern Michigan University)]TJ
10.92 0 Td
( )Tj
-10.92 -1.167 Td
(School of Medicine)Tj
( )Tj
0 -1.167 Td
[(K)17.6 (alamazoo)]TJ
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 0 -2.5 Td
(EDITOR)Tj
/TT0 1 Tf
0 Tw 0 -1.25 Td
(Jonathan Springston)Tj
/T1_0 1 Tf
0.01 Tw 0 -2.5 Td
(EDITOR)Tj
/TT0 1 Tf
0 Tw 0 -1.25 Td
(Jason Schneider)Tj
/T1_0 1 Tf
0 -2.5 Td
(EDITORIAL GROUP MANAGER)Tj
/TT0 1 Tf
0 -1.333 Td
(Leslie Coplin)Tj
/T1_0 1 Tf
0 -2.667 Td
[(ACCREDIT)74 (A)74 (TIONS DIRECTOR)]TJ
/TT0 1 Tf
0 -1.25 Td
(Amy M. Johnson, MSN, RN, CPN)Tj
ET
endstream
endobj
42 0 obj
<>
endobj
43 0 obj
<>
endobj
44 0 obj
<>
endobj
49 0 obj
<>
endobj
50 0 obj
<>stream
HdNV{q)>J\> i\?m 6eȷ<O/fst]~x{_Nϯ7ww˛oxx2r/?2އp?D??yz{qfzOt:m-_7͆"uDsF'OuOD'&2G'j~"7vG?j$O ?O'I?ɟ'$O ?O'I?ɟ'3,Ɵ?gYyV2ee*)U,S,XXVLbbY2Ų++*V(VTPXXQBbbE
ŊnL_//?R_/WU_W+*_WU_W+*_o7M7&o
o7M7&o
:zX.oز>*+zR9OS Mb
endstream
endobj
51 0 obj
<>stream
HtV TT[G}`$(4n5"d\BU!VAXFF1 UNA=̝{` <^ےJ;DS
3nOZXy/V jBǑR;#ѳI-n,